If nucleotide and amino acid sequences within the meaning of Rule 30(1) are disclosed in the European patent application, they are to be represented in a sequence listing which conforms to WIPO Standard ST.25. The sequence listing should, where it is filed together with the application, be placed at the end of the application (see WIPO Standard ST.25, point 3). The sequence listing must be filed in electronic form. Where the European patent application is filed online, the electronic form is to be attached. Data in electronic form must comply with WIPO Standard ST.25, paragraph 39ff. Where the sequence listing is in addition voluntarily filed on paper, the sequence listing on paper must be identical to the information in electronic form. In this case, the applicant or his representative must submit a statement to that effect accompanying the electronic form in accordance with Rule 30(1) and WIPO Standard ST.25. See the Decision of the President of the EPO dated 28 April 2011, OJ EPO 2011, 372 and the accompanying Notice from the EPO dated 28 April 2011, OJ EPO 2011, 376. Where a sequence listing is filed or corrected after the filing date, the applicant is required to submit a statement that the sequence listing so filed or corrected does not include matter which goes beyond the content of the application as filed.
The Receiving Section will inform the applicant of any deficiencies as to the sequence listing or as to the necessary statements and invite him to remedy the deficiencies and pay a late furnishing fee within a non-extendable period of two months. If the requirements of Rule 30 in conjunction with the Decision of the President of the EPO dated 28 April 2011 are not complied with in due time, where appropriate following the invitation to do so from the Receiving Section, which includes the payment of the late furnishing fee, the application will be refused according to Rule 30(3).